| Abstract: |
Urothelial tract tumors are chemosensitive, but long-term benefit is limited to a select few. New agents must be identified. These should be evaluated in carefully designed and executed trials with careful documentation of response. Only those combinations that consistently produce complete remissions should be considered for large-scale comparisons. The effect of stage migration, and inclusion of early-stage patients with an inherently better survival, can be minimized doing these prospective trials. Ultimately, a better understanding of the biology of these tumors may allow more accurate biologic prognostication and selection of therapy for individual patients. |
